Polartechnics Enters Global Sexually Transmitted Infection (STI) Market With A DNA Self-Sampling Device

Published: Feb 18, 2009

Sydney, Feb 18, 2009 (ABN Newswire) - Polartechnics Limited (ASX:PLT)(PINK:PLTFF) proprietary self-sampling device, CerviScreen, has now been adapted to test for STI's including Chlamydia, Gonorrhoea and Trichomoniasis for both men and women. The new self-sampling target market for the STI device is sexually active men and women aged 15 to 50.

Back to news